Certain Board members, senior executives and major shareholders have undertaken to subscribe for shares for a total of approx. SEK 15.5 million by exercising warrants of series 2019/2021

20-01-2021   Regulatory press release

The following board members, senior executives and major shareholders in ADDvise Group AB (publ) (“ADDvise”) have irrevocably undertaken to exercise a total of 23,813,195 warrants of series 2019/2021, which corresponds to a total of approximately 55% of the warrants of series 2019 / 2021 (“The Warrants”). The subscription means that ADDvise will receive issue proceeds of at least SEK 15.5 million. The subscription period for the Warrants runs from and including January 25, 2021 until and including February 8, 2021. Holders of Warrants have the right to subscribe for one (1) new share of series B in ADDvise for SEK 0.65 per share.

  • CEO, Board member and major shareholder, Rikard Akhtarzand, has undertaken to, privately or through company, exercise all his 3,428,508 Warrants, corresponding to an issue proceeds of SEK 2,228,530.
  • Board member, Erland Pontusson, has undertaken to, privately, exercise all his 58,839 Warrants, corresponding to an issue proceeds of SEK 38,245.
  • The Chairman of the Board and major shareholder, Staffan Torstensson, has undertaken to, privately or through company, exercise all his 220,000 Warrants, corresponding to an issue proceeds of SEK 143,000.
  • Major shareholder, Per Åhlgren, has undertaken to, privately or through company, exercise all his 13,781,076 Warrants, corresponding to an issue proceeds of SEK 8,957,699.
  • Major shareholder, Magnus Vahlquist, has undertaken to, privately, exercise all his 6,324,772 Warrants, corresponding to an issue proceeds of SEK 4,111,102.

Full terms and conditions for the warrants of series 2019/2021 were included in the investment memorandum published in connection with the new share issue that was made public on December 12, 2018. The investment memorandum is also available at www.addvisegroup.se.

Note that warrants of series 2019/2021 that are not sold no later than February 4, 2021, or alternatively exercised by February 8, 2021, expire worthless. In order for your warrants of series 2019/2021 not to expire, you must actively subscribe for shares or sell your warrants.

Adviser

Mangold Fondkommission is financial adviser and Advokatfirman Schjødt is legal advisor to ADDvise in connection with the exercise of warrants of series 2019/2021.

For questions regarding the warrants, please contact:

Mangold Fondkommission AB

Tel: +46 8 5030 1595

E-mail: emissioner@mangold.se

For further information:

Rikard Akhtarzand, CEO
Tel: +46 765-25 90 71
E-mail:
rikard.akhtarzand@addvisegroup.se

Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on 20 January 2021 at 08.30 CET.
 

About ADDvise

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business - both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, ca@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

Latest press releases

ADDvise announces preliminary result for 2022 which is stronger than expected

Regulatory

The preliminary result for ADDvise Group for the full year 2022 significantly deviates from what ADDvise Group considers to be current market expectations. [image] The net sales pro forma full year 2022 rolling 12 months amounted to SEK 1,097 million with an adjusted EBITDA pro forma of SEK 241 million. The financial targets for the…

ADDvise receives order worth USD 3.5 million

Regulatory

ADDvise Group AB’s subsidiary Poly Pharmaceuticals Inc has received an order from AxisCare Health Logistics Inc, a company distributing equipment and medical supplies to hospitals, clinics, medical offices and medical equipment suppliers. The order is worth approximately USD 3.5 million. The order consists of delivery of the prescription dietary supplemental Folite, developed and manufactured by…

ADDvise receives order worth USD 1.8 million

Regulatory

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Nasser Saeed Al Hajri & Partners Contracting (NHS & Partners), a leading construction contractor in the United Arab Emirates. The order is worth approximately USD 1.8 million. The order involves the detailed design, supply and installation of an ISO 8 and ISO 7…